Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Conditions
Brief summary
This protocol will study treatment for Ewing sarcoma family of tumors (ESFT) and desmoplastic small round cell tumor (DSRCT). Participants with ESFT will be divided into two treatment groups, A or B, based on tumor characteristics. Group A (standard risk) participants have tumor that is not in the pelvis, has not spread to other parts of the body, and are less than 14 years of age. Because previous clinical trials have shown that standard treatment is very effective for children whose tumors have these characteristics, these participants will receive standard treatment. Group B (high risk) participants are 14 years of age or older or have tumor in the pelvis, or the tumor has spread to other parts of the body. Participants with DSRCT in the abdomen and/or pelvis or with tumor that cannot be removed by surgery alone or has spread to other parts of the body will be included in Group B. Participants in this group are considered high risk because there is a greater chance of tumor recurring following standard treatments currently in use. All participants will be followed and evaluated for 10 years following completion of therapy.
Detailed description
PRIMARY OBJECTIVE: * To estimate the response rate to two initial courses of temsirolimus, temozolomide and irinotecan in previously untreated patients with high-risk Ewing sarcoma family of tumors (ESFT). SECONDARY OBJECTIVES: * To estimate the overall survival and progression-free survival in participants with ESFT treated with these approaches. * To estimate the time to progression in participants with ESFT treated in Group B (high risk). * To estimate the cumulative incidence of local failure following local control paradigm in this trial. Group A: Participants will receive interval compressed (every 2 weeks) alternating courses of chemotherapy with vincristine, doxorubicin, and cyclophosphamide (VDC) and with ifosfamide and etoposide (IE). Doxorubicin will be omitted following a total cumulative dose of 375 mg/m\^2. Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of chemotherapy. Total duration of treatment is approximately 29 weeks. Group B: Participants eligible for the window therapy will receive two courses (21 days duration each) of mTOR inhibitor, temsirolimus, in combination with temozolomide and irinotecan. Irinotecan (20 mg/m\^2) will be administered IV on a protracted schedule of daily for 5 days, 2 days off, repeated daily x 5 \[(qdx5)x2\], temozolomide (100 mg/m\^2) PO daily x 5 days and temsirolimus 35 mg/m\^2 IV weekly on day 1 and 8. Following window treatment (weeks 1 - 6), participants will proceed to induction chemotherapy (weeks 7 - 33) consisting of interval compressed (every 2 weeks) alternating courses of chemotherapy with vincristine, doxorubicin, and cyclophosphamide (VDC) with ifosfamide and etoposide (IE). Doxorubicin will be omitted following a total cumulative dose of 375 mg/m\^2. Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of induction chemotherapy (week 19). Participants whose tumors respond to window therapy will receive temsirolimus, temozolomide and irinotecan at weeks 29 and 31 in place of ifosfamide and etoposide. Following induction therapy, participants will receive six 21-day courses of maintenance therapy consisting of bevacizumab IV on day 1 and daily oral sorafenib and low-dose cyclophosphamide day 1 through day 21.
Interventions
DRUGvincristine
Dosage and route of administration: Infants \< 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m\^2 IV day 1 (max. dose 2 mg).
DRUGdoxorubicin
Dosage and route of administration: Infants \< 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants \> 1 year of age 75 mg/m\^2 CI over 48 hours, days 1-2.
DRUGcyclophosphamide
Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
DRUGifosfamide
Dosage and route of administration: Infants \< 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants \> 12 months of age 1800 mg/m\^2 IV over 60 minutes x 5 days, days 1-5.
DRUGetoposide
Dosage and route of administration: Infants \< 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children \> 1 year 100 mg/m\^2 daily IV over 60 minutes days 1-5.
DRUGtemozolomide
Dosage and route of administration: Temozolomide 100 mg/m\^2 PO once daily, days 1-5.
DRUGtemsirolimus
Dosage and route of administration: Temsirolimus 35 mg/m\^2 IV once day 1 and day 8.
DRUGbevacizumab
Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks.
DRUGsorafenib
Dosage and route of administration: 90 mg/m\^2/dose PO BID
PROCEDUREsurgery
If participant meets the criteria, they will have surgical resection of their tumor.
RADIATIONradiation
If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.
Sponsors
St. Jude Children's Research Hospital
University of Tennessee
University of Florida
Nemours Children's Clinic
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 25 Years
Healthy volunteers
No
Inclusion criteria
* Group A participants must be \<14 years of age at time of diagnosis of histologically proven non-pelvic localized Ewing sarcoma family of tumor (ESFT) involving the bone or soft tissue. * Group B participants must have newly diagnosed of histologically proven ESFT involving the bone or soft tissue and at least one of the following: metastatic disease (must be biopsy proven), or pelvic primary, or ≥14 years of age at the time of diagnosis. * OR Group B participants must be newly diagnosed with intra-abdominal, unresectable or metastatic desmoplastic small round cell tumor. Metastatic site must be biopsy proven. * Age must be ≤25 years. * Adequate bone marrow function defined as a peripheral absolute neutrophil count (ANC) ≥750/m\^3 and platelet count ≥75,000/m\^3 (no transfusion within 7 days of study enrollment). Patients with Ewing sarcoma metastatic to the bone marrow are not required to meet bone marrow criteria for study eligibility and are not evaluable for hematologic toxicity. * Must have adequate renal function based on age. * Must not have had prior chemotherapy or radiation therapy. Emergent radiotherapy to preserve vital organ function is permitted. Participants who receive emergent radiation will not be eligible for window therapy. * Must have adequate hepatic function defined as total bilirubin ≤3.0 mg/dL. * Must have adequate cardiac function defined as shortening fraction ≥28%. * Females of childbearing potential and males able to father a child must be willing to practice acceptable methods of birth control to prevent pregnancy. * Additional criteria for Group B participants who will receive upfront window therapy (does not apply to participants who opt out of window therapy): * Cytochrome P450 CYP3A4 active agents: Must not be taking any of the following potent CYP3A4 inducers or inhibitors within 1 week prior to study entry: azole antifungals (such as fluconazole, voriconazole, itraconazole, ketoconazole), rifampin, phenytoin, phenobarbitol, carbamazepine, grapefruit juice and St. John's wort. * Must have measurable disease. * Must not have received emergent radiation therapy. * Serum triglyceride level ≤ 300 mg/dL and serum cholesterol ≤ 300 mg/dL. * Random or fasting glucose within the upper limits of normal for age. If random glucose is elevated, fasting glucose must be within normal range. * SGOT (AST) and SGPT (ALT) ≤3.0 x upper limit of normal for age.
Exclusion criteria
* Participant is pregnant or breastfeeding. * Inability or unwillingness of research participant or legal guardian/representative to give written informed consent. * Participant has a prior history of malignancy, with the exception of non-melanoma skin cancer. Participants with history of skin cancer must have 5 years elapse since that diagnosis, be in remission, and must not have received chemotherapy, immunotherapy, or radiation therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response to Window Therapy (2 Courses) for Group B (High-risk) - ESFT Participants | at 6 weeks after start of therapy (after 2 initial courses) | Response rate will be defined as the proportion of patients who achieved complete response or partial response (CR+PR) using the World Health Organization (WHO) criteria evaluated after two initial courses of temsirolimus, temozolomide and irinotecan in previously untreated patients with high risk Ewing Sarcoma Family of Tumor (ESFT). Participants who are treated in Group B with Desmoplastic Small Round Cell Tumor (DSRCT) or those who do not receive window therapy will not be included in this analysis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | Maximum of 11 years after the start of therapy | Overall survival (OS) is defined as the time interval from the date on study to the date of death or the date of last follow-up. OS will be estimated using the method of Kaplan-Meier for group A and B participants, respectively. |
| Progression-free Survival | Maximum of 11 years after the start of therapy | Progression free survival (PFS) is defined as the time interval from the date on study to the date of disease progression or death or the date if last follow-up. PFS will be estimated using the method of Kaplan-Meier for group A and B participants, respectively. |
| Time to Progression | Maximum of 11 years after the start of therapy | Median time to progression of group B patients will be estimated from the Kaplan-Meier curve. |
| Local Failure Rate | Maximum of 11 years after the start of therapy | Loco-regional failure is defined as the time interval from date of start of local therapy to date of loco-regional failure. Distant failure or death prior to loco-regional failure will be considered competing events in the analyses. The cumulative incidence of loco-regional failure will be estimated using methods described in Kalbfleisch and Prentice. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORSara M. Federico, MD
St. Jude Children's Research Hospital
Participant flow
Recruitment details
Participants were enrolled at St. Jude Children's Research Hospital between December 2013 and June 2015.
Participants by arm
| Arm | Count |
|---|---|
| Group A (Standard Risk) Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide. Doxorubicin will be omitted following a total cumulative dose of 375 mg/m\^2. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone, or surgery followed by radiation. Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of chemotherapy. Total duration of treatment is approximately 29 weeks. | 1 |
| Group B (High Risk) - ESFT Group B participants with a diagnosis of Ewing Sarcoma Family of Tumor (ESFT). | 16 |
| Group B (High Risk) - DSRCT Group B participants with a diagnosis of Desmoplastic Small Round Cell Tumor (DSRCT). | 6 |
| Total | 23 |
Baseline characteristics
| Characteristic | Group B (High Risk) - ESFT | Total | Group A (Standard Risk) | Group B (High Risk) - DSRCT |
|---|---|---|---|---|
| Age, Continuous | 13.0 years STANDARD_DEVIATION 5.7 | 13.4 years STANDARD_DEVIATION 5.2 | 12.0 years STANDARD_DEVIATION 0 | 14.7 years STANDARD_DEVIATION 4.1 |
| Disease stage Local | 5 participants | 7 participants | 1 participants | 1 participants |
| Disease stage Metastases | 11 participants | 16 participants | 0 participants | 5 participants |
| Primary disease site Other | 10 participants | 12 participants | 1 participants | 1 participants |
| Primary disease site Pelvis | 6 participants | 11 participants | 0 participants | 5 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 2 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 14 Participants | 18 Participants | 1 Participants | 3 Participants |
| Sex: Female, Male Female | 9 Participants | 10 Participants | 0 Participants | 1 Participants |
| Sex: Female, Male Male | 7 Participants | 13 Participants | 1 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| other Total, other adverse events | 1 / 1 | 16 / 16 | 6 / 6 | 22 / 22 |
| serious Total, serious adverse events | 0 / 1 | 1 / 16 | 0 / 6 | 1 / 22 |
Outcome results
Primary
Response to Window Therapy (2 Courses) for Group B (High-risk) - ESFT Participants
Response rate will be defined as the proportion of patients who achieved complete response or partial response (CR+PR) using the World Health Organization (WHO) criteria evaluated after two initial courses of temsirolimus, temozolomide and irinotecan in previously untreated patients with high risk Ewing Sarcoma Family of Tumor (ESFT). Participants who are treated in Group B with Desmoplastic Small Round Cell Tumor (DSRCT) or those who do not receive window therapy will not be included in this analysis.
Time frame: at 6 weeks after start of therapy (after 2 initial courses)
Population: Of the 17 Group B participants with high-risk ESFT, 12 received window therapy and are considered evaluable for this outcome.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Group B (High Risk) - ESFT | Response to Window Therapy (2 Courses) for Group B (High-risk) - ESFT Participants | Partial Response (PR) | 3 participants |
| Group B (High Risk) - ESFT | Response to Window Therapy (2 Courses) for Group B (High-risk) - ESFT Participants | Stable disease (no response) (NR) | 8 participants |
| Group B (High Risk) - ESFT | Response to Window Therapy (2 Courses) for Group B (High-risk) - ESFT Participants | Progressive Disease (PD) | 1 participants |
Secondary
Local Failure Rate
Loco-regional failure is defined as the time interval from date of start of local therapy to date of loco-regional failure. Distant failure or death prior to loco-regional failure will be considered competing events in the analyses. The cumulative incidence of loco-regional failure will be estimated using methods described in Kalbfleisch and Prentice.
Time frame: Maximum of 11 years after the start of therapy
Secondary
Overall Survival
Overall survival (OS) is defined as the time interval from the date on study to the date of death or the date of last follow-up. OS will be estimated using the method of Kaplan-Meier for group A and B participants, respectively.
Time frame: Maximum of 11 years after the start of therapy
Secondary
Progression-free Survival
Progression free survival (PFS) is defined as the time interval from the date on study to the date of disease progression or death or the date if last follow-up. PFS will be estimated using the method of Kaplan-Meier for group A and B participants, respectively.
Time frame: Maximum of 11 years after the start of therapy
Secondary
Time to Progression
Median time to progression of group B patients will be estimated from the Kaplan-Meier curve.
Time frame: Maximum of 11 years after the start of therapy